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Abstract
Background: It is estimated that 5% of the hypertensive patients are resistant to conventional
antihypertensive therapy. Polymorphisms in the endothelial nitric oxide synthase (NOS3) gene
have been associated with high blood pressure levels, but not with resistant hypertension. The aim
of the present study was to investigate if the -786T>C and G894T (Glu298Asp) polymorphisms of
the NOS3 gene were associated with resistant hypertension.
Methods: A prospective case-control observational study was performed. From a series of 950
consecutive patients followed up during 42 months, 48 patients with resistant hypertension were
detected. 232 patients with controlled high blood pressure were also included.
Results:  No differences were observed in the distribution of G894T (Glu298Asp) NOS3
genotypes between the resistant hypertension group and the controlled hypertension patients.
However, genotype -786CC was more frequent in the group of patients with resistant
hypertension (33.3%) than in the group of patients with controlled high blood pressure (17.7%) (p
0.03). Furthermore carriers of allele T (-786TC and -786TT) were more frequent in patients with
controlled hypertension (82.3%) than those with resistant hypertension (66.7%) (Multivariate
analysis; RR 2.09; 95% CI 1.03–4.24; p 0.004).
Conclusion:  Our results indicate that genotype -786C C  o f  t h e  N O S 3  g e n e  i n c r e a s e  t h e
susceptibility to suffer resistant hypertension, which suggest that resistance to conventional
therapy could be determined at the endothelial level.
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Background
Hypertension may be termed resistant when a therapeutic
plan that has included attention to lifestyle measures and
the prescription of at least three drugs including a diuretic
in adequate doses has failed to achieve goal blood pres-
sure (BP) defined as a systolic/diastolic pressure of < 140/
90 mmHg or < 130/80 mmHg in diabetics patients [1].
The prevalence of "true" resistant hypertension (excluding
secondary causes of hypertension, white coat hyperten-
sion, inadequate doses, etc) is less than 5% of the general
hypertension population [2]. In general, resistant hyper-
tension has been reduced to an issue of treatment adher-
ence or suboptimal treatment.
Genetic determinants of human hypertension are poorly
understood although polymorphisms in several genes
have been associated with elevated blood pressure levels.
However, there are only few studies that consider resistant
hypertension from a genetic point of view [3-6].
Causative genes for essential hypertension have been
identified through candidate gene approach. Among the
genes investigated, the endothelial nitric oxide synthase
gene (NOS3) has drawn considerable attention because of
its substantial contributions to BP regulation. Endothelial
nitric oxide synthase (eNOS) mediates the release of nitric
oxide, a potent vasodilator, from endothelial cells; and
the disruption of NOS3 gene leads to hypertension in
mice [7]. Several lines of evidence have also supported
that impaired nitric oxide production directly leads to an
elevation in BP [8]. Hence, several investigators have
examined the NOS3 gene as a potential candidate for
essential hypertension, but its relation with resistant
hypertension has not been verified.
The aim of the present study was to investigate if the pro-
moter (-786T>C) and exon 7 (G894T/Glu298Asp) poly-
morphisms of the eNOS gene are associated with resistant
hypertension and essential controlled hypertension.
Methods
Study subjects
An observational prospective case control single centre
study was performed. Once excluded the secondary causes
of hypertension and those patients who did not adhere to
lifestyle measures, patients were considered to have resist-
ant hypertension when a therapeutic plan that included
lifestyle modification (including smoking cessation and
achieving a body mass index at least < 30 kg/m2) and pre-
scription of at least three drugs including an adequately
dosed diuretic, failed to achieve the target BP of < 140/90
mmHg (< 130/80 in diabetics) on any occasion during
follow-up. These patients were controlled at least every
month, 24 h-Ambulatory Blood Pressure were determined
twice and they never achieve goal BP. Treatment adher-
ence was confirmed in all the patients with analytic con-
trol and adherence tests. Secondary causes of
hypertension as obstructive sleep apnea, primary aldos-
teronism, thyroid diseases, chronic kidney disease, phe-
ocromocytoma, Cushing's syndrome and aortic
coarctation were excluded by clinical and laboratory eval-
uation (urinalysis, complete blood cell count, blood
chemistry profile) [1]. Further evaluations were per-
formed if a secondary cause of hypertension was sus-
pected. Pharmacological treatment of each patient was
reviewed looking for pharmacological agents that could
produce transient or persistent increases in BP (Nonster-
oidal anti-inflammatory drugs, sympathomimetics,
cocaine, amphetamines, other illicit drugs, oral contracep-
tive hormones, adrenal steroid hormones, erythropoietin,
cyclosporine, tacrolimus, licorice, over-the-counter die-
tary and herbal supplements).
Controlled hypertension population was defined as hav-
ing a systolic/diastolic BP of > 140/90 mmHg (> 130/80
mmHg if diabetics) on three separate occasions but con-
trolled (< 140/90 mmHg or < 130/80 mmHg if diabetics)
after treatment during the follow-up.
Of 950 Caucasic hypertensive subjects consecutively
referred to the Hypertension Unit of the University Hospi-
tal of Salamanca during 42 months, 48 resistant hyperten-
sive patients (5.2%) were identified. After statistical
estimation, a total of 232 Caucasics age and sex matched
hypertensive subjects who had achieve BP goals after treat-
ment were also included in the study. 110 healthy subjects
were examined to determine the allelic distribution in a
Caucasian control population.
Patients were seated quietly for at least 5 minutes and
blood pressure measurements were performed at least
twice using a Hawksley random zero mercury sphyg-
momanometer with an appropriate cuff size, and verified
three times with an Omron Automatic Blood Pressure
Monitor, Model HEM-773AC (Omron HealthCare Inc,
Bannockburn, Illinois USA), the mean value of the man-
ual measures were used for the analysis. Ambulatory
blood pressure monitoring (ABPM) (24-hour) was meas-
ured using an Oscar ABPM system (SunTech Medical Inc.,
Morrisville, NC, USA). Target organ damage was assessed
by both echocardiograph and fundoscopy by a single-
operator blinded to the patient's condition. Degree of left
ventricular hypertrophy (LVH) and retinopathy were
determined. Significant retinopathy was defined as grade
≥ 2 and LVH as left ventricular mass > 125 g/m2 in men or
110 g/m2 in women. All patients were treated according to
the recommendations of the Joint National Committee 7
[1]. Informed consent was obtained from all subjects. TheBMC Cardiovascular Disorders 2009, 9:35 http://www.biomedcentral.com/1471-2261/9/35
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study was approved by the Ethical Committee of Univer-
sity of Salamanca and was in accordance with the princi-
ples of the Declaration of Helsinki.
Genotyping for eNOS Gene Polymorphisms
Genomic DNA was isolated from peripheral blood leuko-
cytes as previously reported [9]. The presence of the -
786T>C and G894T alleles was determined by polymerase
chain reaction -restriction fragment length polymorphism
(PCR-RFLP) analysis. PCR was performed with primer
pairs designed to amplify either a 180-bp segment con-
taining the promoter (-786T>C) variant (sense: 5' TGGA-
GAGTGCTGGTGTACCCCA 3'; antisense: 5' GCCTCCAC
CCCACCCTGTC 3') or a 200-bp segment encompassing
exon 7 (sense: 5' AACCCCCTCTGGCCCACTCCC3'; anti-
sense: 5' TCCATCCCACCCAGTCAAT 3'). The PCR frag-
ment containing the -786T>C polymorphism was
subjected to digestion with MspI, which cuts the PCR
product when the T at position -786 is replaced by a C.
The fragment containing exon 7, was digested with MboI,
which cuts only in the presence of T at position 894 (cor-
responding to Asp298). Digested samples were separated
on a 3% ethidium bromide-stained agarose gels and visu-
alized by UV transillumination.
Statistical analysis
All genotype groups obeyed the Hardy-Weinberg equilib-
rium. Normally distributed parametric data were
expressed as mean ± SD, and compared with Student's t-
test. The results obtained for the different groups were
compared using chi square and Fisher's exact test. Logistic
regression, including age and sex as confounding factors,
was applied to evaluate differences in allele frequencies
between subjects. A p-value < 0.05 was regarded as signif-
icant. Odds ratio and 95% confidence intervals (OR; 95%
CI) were also calculated. Sample size and statistical power
were estimated according to the preliminary results
obtained in this study. Sample size was estimated for a
95% confidence intervals and 80% statistical power. All
analyses were performed using Statistical Package for
Social Science (SPSS Inc, Chicago, Illinois, USA) version
13.0.
Results
The distribution by age and sex was similar in the group
of patients with resistant hypertension and in the group of
patients with controlled hypertension. The characteristics
of the population are shown in Table 1. Retinopathy
(grade 2 or more) and left ventricular hypertrophy were
more frequent in resistant hypertension patients (80% vs
53% p 0.02; 75% vs 44% p < 0.001). A longer hyperten-
sion evolution was observed in the group of patients with
resistant hypertension (17.05 ± 12 vs 8.61 ± 8 years; p <
0.001).
The patients with resistant hypertension were treated with
a mean of 3.7 drugs (100% diuretics, 50% ACE inhibitors,
68% Angiotensin II Receptor Antagonists, 70% beta
blockers, 24% alfa blockers, 58% calcium channels block-
ers, 2% others), there were no significant differences
between the resistant hypertension group treatment and
the controlled hypertension group treatment.
Table 1: Demographic characteristics in hypertensive patients (resistant and controlled) and in healthy controls
RESISTANT 
HYPERTENSION
(n = 49)
CONTROLLED 
HYPERTENSION
(n = 232)
HEALTHY CONTROLS
(n = 110)
p value
Sex (male) 32.7% 44.9% 46.3% 0.259
Age (years) 68.5 ± 11.7 63.2 ± 14.9 63.4 ± 15.7 0.07
Body Mass Index (kg/m2) 29.7 ± 3.8 28.05 ± 3.79 0.077
Systolic Blood Pressure 
(mmHg)
164 ± 15 132 ± 10 127 ± 13 < 0.001
Dyastolic Blood Pressure 
(mmHg)
95 ± 9 83 ± 7 79 ± 14 < 0.001
Retinopathy ≥ 2 80% 53% 0.02
OR 1.52 (1.12–2.07)
Left Ventricle Hypertrophy 75.8% 44.1% 0.001
OR 3.96 1.61–9.70
Years of evolution 17.05 ± 12 8.61 ± 8 0.001BMC Cardiovascular Disorders 2009, 9:35 http://www.biomedcentral.com/1471-2261/9/35
Page 4 of 6
(page number not for citation purposes)
Distribution of the 894G>T genotypes
The allelic distribution for the healthy control group was
as follows: GG 39.1%, TG 48.2% and TT 12.7%. There
were no differences with the distribution of the controlled
or resistant hypertension group.
In the same way, no significant association was observed
when we studied the distribution of genotypes and alleles
of the 894G>T NOS3 polymorphism between resistant
hypertensive and controlled hypertensive groups. (Resist-
ant hypertension GG 37.5% GT 41.7% TT 20.8% vs con-
trolled hypertension GG 37.5% GT 48.3% TT 14.2%; p
0.47) (Table 2)
Distribution of the -786T>C genotypes
The allelic distribution for the healthy control group was
as follows: TT 23.6%, TC 52.7% and TT 23.6%. There were
no differences with the distribution of the controlled or
resistant hypertension group.
However, Analysis of the distribution of -786T>C NOS3
genotypes show that genotype -786CC is more frequent in
resistant hypertension patients (Table 2). Moreover, when
we distribute our population in those homozygous for the
-786C allele and those carrying at least one -786T allele we
observed that those homozygous for the -786C allele have
higher risk of suffering resistant hypertension (Multivari-
ate analysis: RR 2.09; 95% CI 1.03–4.24; p 0.004) (Table
3)
Discussion
Vascular endothelial dysfunction is a common character-
istic of various cardiovascular diseases. The maintenance
of regular vascular tone substantially depends on the bio-
availability of endothelium-derived nitric oxide (NO)
synthesized by the endothelial isoform of nitric oxide syn-
thase (eNOS). eNOS is coded by the NOS3 gene located
at 7q35. We compared the distribution of the -786T>C
and G894T (Glu298Asp) NOS3 polymorphisms in
patients with controlled and resistant hypertension.
The association between NOS3 gene polymorphisms and
essential hypertension is not clear yet [10], and there are
only a few studies investigating the association of these
polymorphisms with resistant hypertension [5,11].
We did not find any difference in the distribution of gen-
otypes of the G894T (Glu298Asp) polymorphism
between the groups of patients with controlled and resist-
ant hypertension. Thus, our results indicate that the
G894T (Glu298Asp) polymorphism of the NOS3 gene
did not modify the susceptibility to suffer resistant hyper-
tension in our population. G894T (Glu298Asp) polymor-
phism is located in exon 7 of the NOS3 gene and has been
associated with the development of hypertension [12]
and endothelial dysfunction in healthy, smokers young
adults [13]. Furthermore functional consequences of the
Glu298Asp NOS3 variation have been demonstrated in
human endothelium [14]. Nevertheless, the relation of
this polymorphism with essential hypertension is not
clear [15]. Recent studies described that Asp298 eNOS is
more vulnerable to enzymatic cleavage in cell lysates as
compared with the Glu298 protein and could potentially
alter protein-protein interactions in dimer formation [16].
The only association between Glu298Asp polymorphism
and resistant hypertension was reported by Jachymova et
al, they found a higher frequency of the T allele in patients
with hypertension and resistant hypertension compared
to a control group but they did not compared hyperten-
sion versus resistant hypertension [5].
However, we found differences in the distribution of the -
786T>C NOS3 genotypes being genotype CC more fre-
quent in the resistant hypertension group. To the best of
our knowledge, this is the first time that the CC genotype
has been associated with resistant hypertension. Recently,
this association was investigated by Sandrim et al, their
results suggested that eNOS haplotypes are not associated
with resistance to antihypertensive therapy [11]. However
the populations investigated are different and the fre-
quencies of the alleles even in the hypertension group are
different from the ones presented in the current manu-
script.
The -786CC NOS3 genotype has been associated with a
decrease in the activity of the NOS3 promoter and a
Table 2: 894 G>T Genotypes distribution in resistant hypertension patients and in patients with controlled hypertension.
-894G>T NOS3
GG GT TT TOTAL (n) P
RESISTANT HYPERTENSION 18 (37.5%) 20 (41.7%) 10 (20.8%) 48 0.47
CONTROLLED HYPERTENSION 87 (37.5%) 112 (48.3%) 33 (14.2%) 232
TOTAL (n) 105 132 43 280BMC Cardiovascular Disorders 2009, 9:35 http://www.biomedcentral.com/1471-2261/9/35
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decrease in NOS3 mRNA levels [17]. It has been previ-
ously reported that subjects with the -786CC genotype
had significantly higher systolic blood pressures and were
more likely to be hypertensive [17]. Moreover, -786C
NOS3 allele has been related with impaired activity of the
eNOS enzyme, coronary spasm, and impaired endothe-
lium-dependent vasodilatation in CAD patients [17,18].
On the other hand it has been reported that subjects who
were homozygous for the T allele of the -786 T >C NOS3
polymorphism exhibited a significantly higher increase of
forearm blood flow in response to vasodilators (acetyl-
choline, nitroprussiate) than CT and CC subjects [19].
Finally, in this study retinopathy and left ventricular
hypertrophy were more frequent in resistant hypertension
patients. These findings could be partially explained by a
longer hypertension evolution in the group of patients
with resistant hypertension. However it has been previ-
ously described that a variant of eNOS gene (Glu298Asp)
could be an independent risk factor for left ventricular
hypertrophy in human essential hypertension [20,21]. In
the same way the association of eNOS polymorphisms
and retinopathy has been investigated with inconsistent
results [22-24].
Our data suggest that promoter variants in the NOS3 gene
may play a role in the pathogenesis of resistant hyperten-
sion. We propose that the risk to suffer resistant hyperten-
sion could be determined at least partially at genetic level.
However, we consider that resistant hypertension is a
multifactorial syndrome and polymorphisms in other
genes as well as environmental factors take part in its
development.
Limitations
This is a single-centre study with a limited number of
patients; the findings of the present study should be con-
firmed in at least a second population. This cohort of
patients has been used in other study [6]. No correction of
p-values for multiple comparisons has been applied in
this study.
In summary, -786CC NOS3 genotype could be a signifi-
cant contributing factor to resistant hypertension and may
be a genetic marker of genetic predisposition to resistant
hypertension. These results further support the central
role of endothelial-derived NO in the pathogenesis and
response to treatment of hypertension, and could open a
new perspective in the therapeutic approach of resistant
hypertension.
Conclusion
-786CC NOS3 genotype increase the susceptibility to suf-
fer resistant hypertension and may be a genetic marker of
genetic predisposition to resistant hypertension.
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